# OnCo record nct04191135 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04191135/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04191135", "NCT04191135" ;
  schema:name "Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)"@en ;
  schema:description "Replacing chemotherapy with olaparib alongside pembrolizumab did not improve the primary progression-free survival outcome in metastatic TNBC."@en ;
  schema:url <https://onco.cc/trials/nct04191135/> ;
  schema:dateModified "2026-10-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04191135>, <https://doi.org/10.1158/1078-0432.CCR-25-1818> ;
  onco:status "withdrawn" ;
  onco:phase "2" ;
  schema:startDate "2019-12-19" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/tnbc/> ;
  onco:targets <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/> .